SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009606
Filing Date
2023-05-12
Accepted
2023-05-12 16:30:48
Documents
63
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nrbo-20230331x10q.htm   iXBRL 10-Q 968071
2 EX-31.1 nrbo-20230331xex31d1.htm EX-31.1 17146
3 EX-32.1 nrbo-20230331xex32d1.htm EX-32.1 11052
  Complete submission text file 0001558370-23-009606.txt   4750890

Data Files

Seq Description Document Type Size
4 EX-101.SCH nrbo-20230331.xsd EX-101.SCH 43719
5 EX-101.CAL nrbo-20230331_cal.xml EX-101.CAL 26089
6 EX-101.DEF nrbo-20230331_def.xml EX-101.DEF 163622
7 EX-101.LAB nrbo-20230331_lab.xml EX-101.LAB 353198
8 EX-101.PRE nrbo-20230331_pre.xml EX-101.PRE 262986
57 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20230331x10q_htm.xml XML 781605
Mailing Address 200 BERKELEY ST. FL 19 BOSTON MA 02116
Business Address 200 BERKELEY ST. FL 19 BOSTON MA 02116 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 23916319
SIC: 2834 Pharmaceutical Preparations